Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C17H24N6O4 |
| Molecular Weight | 376.4103 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)N2C=NC3=C2N=CN=C3NC4CCCC4
InChI
InChIKey=GWVQGVCXFNYGFP-PFHKOEEOSA-N
InChI=1S/C17H24N6O4/c1-2-18-16(26)13-11(24)12(25)17(27-13)23-8-21-10-14(19-7-20-15(10)23)22-9-5-3-4-6-9/h7-9,11-13,17,24-25H,2-6H2,1H3,(H,18,26)(H,19,20,22)/t11-,12+,13-,17+/m0/s1
| Molecular Formula | C17H24N6O4 |
| Molecular Weight | 376.4103 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Selodenoson (formerly DTI-0009) was developed by Aderis Pharmaceutical as a selective adenosine A1 full agonist to control heart rate in patients with atrial fibrillation while minimizing changes in blood pressure or decreases in heart function. The drug was studied in phase II clinical trial to treat the patients with supraventricular arrhythmias, however, this study was discontinued.
Approval Year
Sample Use Guides
In the trial, patients were randomized to receive placebo or selodenoson at 2, 4, 6, 8, 10 or 12 mcg/kg doses as a 15-minute infusion. The heart rate was reduced by all doses at 5, 15 (end of infusion) and 30 minutes after beginning the infusion.
Route of Administration:
Intravenous
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:18:38 GMT 2023
by
admin
on
Fri Dec 15 16:18:38 GMT 2023
|
| Record UNII |
103G5E953K
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29707
Created by
admin on Fri Dec 15 16:18:38 GMT 2023 , Edited by admin on Fri Dec 15 16:18:38 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C522396
Created by
admin on Fri Dec 15 16:18:38 GMT 2023 , Edited by admin on Fri Dec 15 16:18:38 GMT 2023
|
PRIMARY | |||
|
3082555
Created by
admin on Fri Dec 15 16:18:38 GMT 2023 , Edited by admin on Fri Dec 15 16:18:38 GMT 2023
|
PRIMARY | |||
|
C75135
Created by
admin on Fri Dec 15 16:18:38 GMT 2023 , Edited by admin on Fri Dec 15 16:18:38 GMT 2023
|
PRIMARY | |||
|
300000034406
Created by
admin on Fri Dec 15 16:18:38 GMT 2023 , Edited by admin on Fri Dec 15 16:18:38 GMT 2023
|
PRIMARY | |||
|
110299-05-3
Created by
admin on Fri Dec 15 16:18:38 GMT 2023 , Edited by admin on Fri Dec 15 16:18:38 GMT 2023
|
PRIMARY | |||
|
CHEMBL2107371
Created by
admin on Fri Dec 15 16:18:38 GMT 2023 , Edited by admin on Fri Dec 15 16:18:38 GMT 2023
|
PRIMARY | |||
|
103G5E953K
Created by
admin on Fri Dec 15 16:18:38 GMT 2023 , Edited by admin on Fri Dec 15 16:18:38 GMT 2023
|
PRIMARY | |||
|
PP-01
Created by
admin on Fri Dec 15 16:18:38 GMT 2023 , Edited by admin on Fri Dec 15 16:18:38 GMT 2023
|
PRIMARY | |||
|
8466
Created by
admin on Fri Dec 15 16:18:38 GMT 2023 , Edited by admin on Fri Dec 15 16:18:38 GMT 2023
|
PRIMARY | |||
|
DTXSID00149201
Created by
admin on Fri Dec 15 16:18:38 GMT 2023 , Edited by admin on Fri Dec 15 16:18:38 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
TARGET -> AGONIST |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
